In this episode, Josefine Persson, Genentech associate director, and Ben Locwin, Black Diamond Networks vice president of project solutions, discuss how the cost of oversampling from clinical GMP runs versus development sources equates to high expenses and lost opportunities in moving a new project into GMP manufacturing.

Persson also talks about the role judicious sampling plays in testing and verifying process operations and how she worked with various Genentech departments to reduce product sampling volumes by more than 50 percent. She goes on to discuss the importance of changing the company mindset to encourage behaviors based on department needs rather than wants, especially with smaller indication products. Finally, Persson details how conservative clinical GMP sampling dramatically impacts direct and indirect costs, increases speed to market, and reduces environmental impact.

Links from this episode:
Evaluating Biopharma
Genentech
Black Diamond Networks

Evaluating Biopharma boiler: Evaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today’s decision makers can leverage their knowledge, learn from their successes, and avoid repeating similar mistakes. This series offers a new guest and moderator with each episode and aims to equip executives and science leaders with the necessary information to make better business and process decisions. The Evaluating Biopharma podcast is a reproduction of content originally presented at recent Evaluating Biopharma digital and educational networking events.